The U.S. Food and Drug Administration (FDA) has approved Takeda’s oveporexton, which will be marketed under the brand name Orzeyful, for the treatment of narcolepsy type 1 (NT1). According to the agency, the therapy is the first orexin receptor 2 agonist to receive approval, and the first medicine indicated to address the full range of symptoms associated with narcolepsy type 1 rather than targeting individual manifestations of the disorder. The drug will become available following completion of the scheduling process conducted by the U.S. Drug Enforcement Administration (DEA).
Approval Introduces a New Treatment Approach for Narcolepsy Type 1
Narcolepsy type 1 is a rare neurological sleep disorder caused by the loss of brain cells that produce orexin, a chemical messenger involved in regulating wakefulness, sleep, and muscle tone. Takeda estimates that approximately 120,000 people in the United States are affected by the condition.
People living with narcolepsy type 1 can experience excessive daytime sleepiness, sudden loss of muscle tone known as cataplexy, cognitive symptoms and disrupted nighttime sleep. Orzeyful is designed to directly address the loss of orexin signaling that underlies the disease. The twice-daily oral treatment is the first approved therapy to act on the orexin system and the first medicine approved to treat narcolepsy type 1 as a unified disorder.
The FDA stated that no previously approved medicine for narcolepsy type 1 addressed the condition in this manner.
Clinical Studies Demonstrated Improvements Across Multiple Measures
The approval was supported by findings from the Phase 3 FirstLight and RadiantLight studies. In these trials, patients treated with Orzeyful experienced significant improvements compared with placebo across several measures, including cataplexy and quality of life.
The studies also showed improvements in wakefulness. According to the drug’s label, patients receiving Orzeyful recorded improvements of up to 9.8 points on the Epworth Sleepiness Scale compared with placebo. The FDA also noted that participants receiving the treatment demonstrated better ability to remain awake during the day than those who received placebo.
Discussing the significance of the approval, Jefferies told investors that “restoration of orexin signaling is likely to reshape the treatment paradigm,” citing the efficacy results observed in clinical testing.
Jefferies also stated that the therapy’s performance compared favorably with currently available narcolepsy treatments. The firm highlighted efficacy as a key distinguishing feature of the newly approved drug.
Market Availability and Scheduling Review
Although approved by the FDA, Orzeyful remains under review by the DEA for controlled substance classification. Takeda said a decision is expected within 90 days.
Jefferies noted that the drug appears to have a manageable abuse potential and suggested it could receive a Schedule IV designation. The firm stated that such a classification would be less restrictive than some other treatments used in narcolepsy.
Following the DEA’s determination, Takeda plans to make Orzeyful available through a specialty pharmacy network for healthcare providers and patients in the United States.
Truist Securities described Orzeyful as a mechanistically differentiated entrant in the narcolepsy treatment market and noted that the FDA framed narcolepsy type 1 as a complete disorder rather than a collection of separate symptoms. The analysts also pointed out that the current approval applies only to adult patients.
The FDA approval means Orzeyful can move forward toward commercial availability once the DEA scheduling review is completed.
Orzeyful has gained attention following its approval as the first orexin agonist for narcolepsy type 1. The development of Orzeyful represents an important step in targeting the underlying orexin pathway associated with narcolepsy.
Unlike treatments that primarily manage symptoms, Orzeyful is designed to work through the orexin system, which plays an important role in regulating wakefulness and sleep. The approval of Orzeyful could therefore provide physicians with a new therapeutic approach for patients affected by narcolepsy type 1.
How Orzeyful May Help Patients
Orzeyful works by activating orexin receptors involved in maintaining wakefulness. In narcolepsy type 1, orexin signaling is impaired, contributing to excessive daytime sleepiness and other symptoms.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
